Strategies for Optimizing Population Management of Patients With RA

October 23, 2017

Maureen McMahon, MD, associate clinical professor at the UCLA David Geffen School of Medicine, will update conference attendees on the novel Rheumatoid Arthritis therapies that can improve patient outcomes.

During her presentation, entitled “Optimizing Treatment Strategies in the Management of Rheumatoid Arthritis: Novel Therapies for Improved Patient Outcomes,” on October 27, Dr McMahon will outline the overarching concepts of rheumatoid arthritis treatment, and the novel agents being used for treatment of patients with established disease.

Dr McMahon will give the audience an idea of a typical rheumatoid arthritis treatment plan by presenting case studies that highlight the disease’s presentation. She will also compare treatment of a typical patient in the ear before biologic treatments to after the introduction of the groundbreaking therapies. 

Before biologics, 50% of patients could expect to see joint damage within 2 years, followed by debilitating disease within 10 years—often leading to early death.  She will also highlight how things have changed in the biologic era, since the introduction of rituximab, abatacept, golimumab, and certolizumab in 2008.

Dr McMahon will break down how targeted therapy can improve patient disease progression through the use of disease modifying antirheumatic drugs (DMARDs). Other agents that Dr McMahon will cover include IL-1 blockers, TNF blockers, IL-6 receptor blockers, JAK inhibitors, and B-cell targeting therapies. 

The presentation will also cover how combination therapy with DMARDs need frequent monitoring to adjust treatment, monitor for adverse events—which includes multiple rheumatologists visits per year. 

Dr McMahon will also cover topics including treatment failure, switching biologics, strategies for successful switching, therapy withdraw, RA prevention strategies, and other future directions for RA treatment. 

“The broad range of agents, administration routes (including new oral agents), and mechanisms of action enhance clinical opportunities,” Dr McMahon wrote in her upcoming presentation. “Compliance, individualized regimens, and effective patient-doctor relationships are always key to the best outcomes.”